[Successful child delivery in treatment-free remission of chronic myeloid leukemia after discontinuation of dasatinib].

Abstract

A 21-year-old woman was diagnosed with chronic myeloid leukemia in March 2014. The patient and her family did not wish to freeze eggs before dasatinib initiation. After 66 months of oral dasatinib administration and 40 months of MR4.5 maintenance, the patient requested to discontinue dasatinib due to a desire to conceive. MR4.5 maintenance was continued, and she achieved spontaneous pregnancy 6 months after dasatinib discontinuation. The patient gave birth to a normal baby 13 months later and was on MR4.5 maintenance 21 months after dasatinib discontinuation.

• Authors: Natsuki Hirose, Shin Fujisawa, Takayuki Sakuma, Ayako Matsumura, Kazuho Miyashita, Yuki Nakajima, Hideaki Nakajima
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 63 Issue 2 Pg. 114-116 ( 2022) ISSN: 0485-1439 [Print] Japan
• PMID: 35264501 (Publication Type: Case Reports, Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Dasatinib

Topics

• Dasatinib (therapeutic use)
• Female
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Protein Kinase Inhibitors
• Treatment Outcome
• Young Adult